SCHEMBL1174440

SCHEMBL1174440

CCc1cc(N)ccc1/C=C/C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 1/20 0.49
▸ EGFR P00533 1/20 0.45
▸ MIF P14174 1/20 0.44
▸ PTGER3 P43115 7/20 0.43
▸ PTGER2 P43116 7/20 0.43
▸ PTGER4 P35408 5/20 0.43
▸ KDM4E B2RXH2 3/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ GAA P10253 2/20 0.43
▸ PTGS2 P35354 2/20 0.43
▸ ESR1 P03372 1/20 0.43
▸ PTGS1 P23219 1/20 0.43
▸ TBXA2R P21731 4/20 0.42
▸ PTGDR Q13258 4/20 0.42
▸ PTGFR P43088 3/20 0.42
▸ EIF2AK2 P19525 1/20 0.42
▸ CSNK2A2 P19784 1/20 0.42
▸ CSNK2B P67870 1/20 0.42
▸ CSNK2A1 P68400 1/20 0.42
▸ PTGIR P43119 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1174443 1.00 NPSR1 (0.49) NPSR1EGFRMIFPTGER3PTGER2
SCHEMBL10865615 0.85 NPSR1 (0.47) NPSR1EGFRMIFPTGER3PTGER2
SCHEMBL11791653 0.85 ATG4B (0.43) NPSR1KDM4EALDH1A1SMN1; SMN2
SCHEMBL11791639 0.85 ATG4B (0.43) NPSR1KDM4EALDH1A1SMN1; SMN2
SCHEMBL11791982 0.84 ATG4B (0.45) —
SCHEMBL11791976 0.84 ATG4B (0.45) —
SCHEMBL3685251 0.83 EGFR (0.53) EGFRMIFPTGER3PTGER2PTGER4
SCHEMBL9447849 0.83 MIF (0.60) EGFRMIFPTGER3PTGER2PTGER4
SCHEMBL10350184 0.83 MIF (0.60) EGFRMIFPTGER3PTGER2PTGER4
SCHEMBL3685249 0.83 EGFR (0.53) EGFRMIFPTGER3PTGER2PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114746512-A Composition for forming cured film, alignment material, and phase difference material 日产化学株式会社 2022-07-12 — — CN disclosed
CN-106980233-B Cured film-forming composition, alignment material, and phase difference material 日产化学工业株式会社 2021-07-13 — — CN disclosed
CN-112384834-A Cured film, alignment material, and phase difference material 日产化学株式会社 2021-02-19 — — CN disclosed
CN-107463066-B Cured film-forming composition, alignment material, and phase difference material 日产化学工业株式会社 2020-10-30 — — CN disclosed
US-9823400-B2 Cured film formation composition, orientation material, and retardation material NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2017-11-21 — — US disclosed
US-9598547-B2 Cured-film formation composition, orientation material, and retardation material NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2017-03-21 — — US disclosed
US-9405154-B2 Method for manufacturing orientation material, orientation material, method for manufacturing retardation material, and retardation material NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-08-02 — — US disclosed
US-9255191-B2 Cured-film formation composition, orientation material, and retardation material NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-02-09 — — US disclosed
US-20160033702-A1 CURED FILM FORMATION COMPOSITION, ORIENTATION MATERIAL, AND RETARDATION MATERIAL NISSAN CHEMICAL IND LTD (JP) 2016-02-04 — — US disclosed
US-9244199-B2 Cured film formation composition, orientation material, and retardation material NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2016-01-26 — — US disclosed
US-20070142380-A1 Viral Polymerase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-21 — — US disclosed
US-7223785-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-29 — — US disclosed
EP-1587787-A1 VIRAL POLYMERASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2005-10-26 — — EP disclosed
US-6841566-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM, LTD. (CA) 2005-01-11 — — US disclosed
US-20040171626-A1 Viral polymerase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-09-02 — — US disclosed
WO-2004065367-A1 VIRAL POLYMERASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-08-05 — — WO disclosed
EP-1411928-A1 VIRAL POLYMERASE INHIBITORS BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2004-04-28 — — EP disclosed
US-20030236251-A1 Viral polymerase inhibitors BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2003-12-25 — — US disclosed
WO-2003007945-A1 VIRAL POLYMERASE INHIBITORS BOEHRINGER INGELHEIM (CANADA) LTD. (CA) 2003-01-30 — — WO disclosed
US-4101543-A DYES FOR CELLULOSE ACETATES, AROMATIC POLYESTERS OR POLYAMIDES PRODUITS CHIMIQUES UGINE KUHLMANN (FR) 1978-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236251-A1 Viral polymerase inhibitors POLR2H, CTDSP1, POLR2E NPSR1 3559/4885EGFR 916/4885MIF 3192/4885
US-20040171626-A1 Viral polymerase inhibitors POLM, MED1, POLR2H NPSR1 4058/4885EGFR 3677/4885MIF 3718/4885
US-20070142380-A1 Viral Polymerase Inhibitors POLM, POLR2H, POLR2A NPSR1 2626/4885EGFR 3691/4885MIF 3479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback